Once again, Vertex Pharmaceuticals (VRTX) is battling a government over the price of a cystic fibrosis drug.

The latest row is taking place in the U.K., where the National Health Service is refusing to provide coverage unless the drug maker lowers the price for Orkambi. The haggling has, in fact, been underway for nearly two years, but the impasse has sparked frustration and debate in the U.K. Parliament after more than 114,000 people signed a petition demanding coverage.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy